H|T: The Healthtech Times – Ozempic maker Novo Nordisk buys Montréal’s Inversago for $1 billion
Plus: US Senator questions ethics of Google’s Med-PaLM 2.
Plus: US Senator questions ethics of Google’s Med-PaLM 2.
Plus: Silofit closes its doors, VoxNeuro raises $4.5M to scale brain performance.
Trio joins growing list of Canadian tech firms that have restructured or ceased operating during the downturn.
Plus: Vital Bioscience reveals desktop blood tester with big backers.
Plus: Halifax’s 3D BioFibR secures $3.52M for automated collagen fibre manufacturing.
After the bloody mess at Theranos, Vital is among the new wave of startups developing accessible diagnostics.
Dialogue will maintain its head office in Montréal and operate as a standalone entity as part of Sun Life Canada.
An eight-year collaboration has ended in acquisition for the two Toronto healthtech startups.
Funding is split between five companies and one business hub in Toronto, as well as one Ottawa-based firm.
3D BioFibR’s collagen fibre can be used as an artificial tendon in soft tissue repair research.
Plus: Ditch Labs wants to treat nicotine addiction with tech.
Plus: There’s a $10M bounty to integrate AI into food production.
Well Health revised its annual revenue guidance sharply upwards after the purchase for an undisclosed sum.
The US biotech firm opened a new Canadian HQ in Toronto last month.